ストックスクリーナーアプリを入手
0.9841
4.46%
-0.0459
アフターアワーズ：
1.00
0.0159
+1.62%
前日終値:
$1.03
開ける：
$1.06
24時間の取引高:
48.25M
Relative Volume:
10.84
時価総額：
$330.00M
収益：
-
当期純損益:
$-63.08M
株価収益率:
-3.6448
EPS:
-0.27
ネットキャッシュフロー:
$-72.53M
1週間 パフォーマンス:
-7.16%
1か月 パフォーマンス:
+2.74%
6か月 パフォーマンス:
+16.38%
1年 パフォーマンス:
-31.18%
1日の値動き範囲:
$0.9841
$1.09
1週間の範囲:
$0.954
$1.15
52週間の値動き範囲:
$0.515
$1.979
Ocugen Inc Stock (OCGN) Company Profile
OCGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9841 | 330.00M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-15 | 開始されました | Maxim Group | Buy |
| 2023-03-01 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 開始されました | Mizuho | Buy |
| 2022-06-15 | 再開されました | ROTH Capital | Buy |
| 2022-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 開始されました | Noble Capital Markets | Outperform |
| 2021-06-11 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-05-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
すべてを表示
Ocugen Inc (OCGN) 最新ニュース
Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment - Yahoo Finance
Ocugen to Release New Investor Presentation - TipRanks
Ocugen gets FDA clearance to begin mid-stage study of OCU410ST - MSN
OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga
Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha
Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA - Ophthalmology Times
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen
Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial - MarketScreener
Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial - GuruFocus
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New - GuruFocus
FDA clears Ocugen’s phase 2/3 trial for Stargardt disease therapy - Investing.com
Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention - MSN
Ocugen To Present at BIO International Convention 2025 | OCGN St - GuruFocus
Ocugen To Present at BIO International Convention 2025 - Ocugen
Ocugen To Present at BIO International Convention 2025 | OCGN Stock News - GuruFocus
Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases - Nasdaq
Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN
Ocugen Secures Licensing Agreement for OCU400 in Korea - MSN
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen, Inc. (NASDAQ:OCGN) Position Boosted by Wellington Management Group LLP - Defense World
Ameriprise Financial Inc. Invests $30,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Signs License Agreement for OCU400 in Korea - TipRanks
Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times
Ocugen stock rises on Korean licensing deal for gene therapy By Investing.com - Investing.com Nigeria
Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com Australia
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus
Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha
BNP Paribas Financial Markets Acquires Shares of 36,859 Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - MarketScreener
Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen
Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400 - marketscreener.com
Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada
Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks
Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea - marketscreener.com
Ocugen, Inc. Announces Signing of Binding Term Sheet for the Lic - GuruFocus
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus
Ocugen, Inc. Announces Signing of Binding Term Sheet for - GlobeNewswire
Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene ... - Bluefield Daily Telegraph
OCGNOcugen Provides Business Update with First Quarter 2025 Financial Results - Revista ADVFN
Ocugen, Inc. (NASDAQ:OCGN) Stock Position Raised by ProShare Advisors LLC - Defense World
Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy - VISTA.Today
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen Receives Rare Pediatric Disease Designation for OCU410ST - MSN
FDA awards Ocugen drug with Rare Pediatric Disease Designation - Pennsylvania Business Report -
Ocugen’s Gene Therapy OCU410ST Nets Rare Pediatric Disease Designation for ABCA4-Associated Retinopathies - CGTLive®
Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - MSN
Ocugen Inc (OCGN) 財務データ
収益
当期純利益
現金流量
EPS
Ocugen Inc (OCGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Fernandes Prabhavathi | Director |
Nov 26 '24 |
Buy |
0.91 |
10,000 |
9,095 |
10,000 |
| Castillo Kirsten | Director |
Nov 22 '24 |
Buy |
0.91 |
25,000 |
22,848 |
75,000 |
1.11%
1.70%
大文字化:
|
ボリューム (24 時間):